Chemistry:Teneligliptin
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Trade names | Tenelia |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C22H30N6OS |
| Molar mass | 426.58 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Teneligliptin (INN; trade name Tenelia) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".[1]
Creation
It was created by Mitsubishi Tanabe Pharma and launched in September 2012 by both Mitsubishi Tanabe Pharma and Daiichi Sankyo in Japan .[2]
Licensing and use
Japan/Korea/India/Argentina
It is approved for use in Japan, Argentina, Korea and India.[3]
Pharmacology
Teneligliptin has unique J-shaped or anchor locked domain structure because of which it has a potent inhibition of DPP 4 enzyme.
Teneligliptin significantly controls glycemic parameters with safety. No dose adjustment is required in renally impaired patients.[4]
References
- ↑ "Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes". Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 6: 187–195. 2013. doi:10.2147/DMSO.S35682. PMID 23671395.
- ↑ "TENELIA® 20mg tablets, a Treatment for Type 2 Diabetes Mellitus Approval of Partial Change in Indication to Lift Restrictions in Combination Therapy". Media & Investors. Daiichi Sankyo. 20 December 2013. http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006054.html.
- ↑ "Teneligliptin (Antidiabetic), Chapter: To Market, To Market - 2012". Annual Reports in Medicinal Chemistry. 48. 2013. pp. 523–524. doi:10.1016/b978-0-12-417150-3.00028-4. ISBN 978-0-12-417150-3.
- ↑ "A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site". Biochemical and Biophysical Research Communications 434 (2): 191–196. May 2013. doi:10.1016/j.bbrc.2013.03.010. PMID 23501107.
 |  |
